✦ LIBER ✦

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer

✍ Scribed by Rugo, Hope S.; Campone, Mario; Amadori, Dino; Aldrighetti, Daniela; Conte, PierFranco; Wardley, Andrew; Villanueva, Cristian; Melisko, Michelle; McHenry, M. Brent; Liu, David; Lee, Francis; Pivot, Xavier

Book ID: 121634081
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 333 KB
Volume: 139
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-013-2552-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Randomized Phase II Study of Paclitaxe

A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer

✍ Adam Brufsky; Karen Hoelzer; Thaddeus Beck; Robert Whorf; Mark Keaton; Padma Nad 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 441 KB

Axitinib or Bevacizumab Plus FOLFIRI or

Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study

✍ Bendell, Johanna C.; Tournigand, Christophe; Swieboda-Sadlej, Anna; Barone, Carl 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 292 KB

A phase II study of paclitaxel plus carb

A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma

✍ Edith A. Perez; David W. Hillman; Philip J. Stella; James E. Krook; Lynn C. Hart 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 3 views

## BACKGROUND. This Phase II multicenter study evaluated the efficacy and toxicity of paclitaxel (200 mg/m 2 by 3-hour infusion) with carboplatin (area under the curve 6 mg/mL per minute) administered every 3 weeks as first-line therapy for women with metastatic breast carcinoma. ## METHODS. Eligi

Final results of a phase II study ofnab-

Final results of a phase II study ofnab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

✍ Christopher Lobo; Gilberto Lopes; Odalys Baez; Aurelio Castrellon; Annapoorna Fe 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 268 KB

A randomized phase III trial of paclitax

A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern cooperative oncology group trial E2100

✍ R. Zon; Miller; M. Wang; J. Gralow; M. Dickler; M. Cobleigh; E. Perez; T. Shenki 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 129 KB

Sunitinib Plus Paclitaxel Versus Bevaciz

Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial

✍ Nicholas J. Robert; Mansoor N. Saleh; Devchand Paul; Daniele Generali; Laurent G 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 798 KB